Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 in Unresectable MPNST With Homozygous MTAP Deletion
NCT07549022Phase 2Recruiting
- Start
- Aug 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MRTX1719 in malignant peripheral nerve sheath tumor (MPNST). Primary endpoint: Objective Response Rate at 2 years. Started Aug 2026; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT07549022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549022.